• Dye Models for Small Biopsies in Pathology

  2026-10-06

  The 2023 study by Nonsiri and colleagues examined whether visible dye markers could reduce the risk of losing or overlooking very small biopsy fragments during tissue preparation. Hematoxylin, merbromin, and Alcian blue improved visual recognition, but hematoxylin was favored because the authors reported lower toxicity concerns and no interference with routine slide interpretation.

• WM-8014 and the KAT6A Senescence Opportunity

  2026-10-05

  RESTRICT-seq positions KAT6A as a potentially important epigenetic dependency in squamous cell carcinoma resistance. This article examines how WM-8014 can help translational researchers connect that genetic signal to reversible KAT6A/B inhibition, senescence biology, and more disciplined pharmacologic validation—while keeping the evidence boundaries clear.

• Cl-Amidine and the Translational Logic of PAD4 Biology

  2026-10-05

  PAD4 inhibition is moving from a narrow enzymology question toward a broader translational framework spanning NET biology, cancer research, inflammatory disease, and septic shock models. This evidence-led perspective examines how Cl-Amidine can help connect mechanism, phenotype, and clinical relevance without overstating preclinical findings.

• Masitinib (AB1010) Product Overview

  2026-10-04

  Masitinib (AB1010; SKU A2942) is cataloged by APExBIO as a phenylaminothiazole-type tyrosine kinase inhibitor associated with KIT and PDGFRα/β research. No matched paper evidence was provided, so this overview describes product identity and stated conceptual scope only.

• WEHI-539 and the Logic of Selective BCL-XL Inhibition

  2026-10-03

  WEHI-539 is a selective BCL-XL inhibitor that helps researchers interrogate how mitochondrial apoptosis depends on the balance between prosurvival and pro-apoptotic BCL-2 family proteins. This thought-leadership analysis connects its reported biochemical and cellular profile with findings from Campbell et al. on MCL-1 dependence in breast cancer, while distinguishing direct evidence from translational inference and outlining the questions that matter for biomarker-led development.

• Cl-Amidine (trifluoroacetate salt) Assay Guide

  2026-10-02

  This scenario-driven guide explains how biomedical researchers can use Cl-Amidine (trifluoroacetate salt), SKU C3829, to design more interpretable PAD4 enzyme activity, viability, proliferation, and cytotoxicity experiments. It covers formulation controls, dose interpretation, storage, cross-study comparisons, and practical product-selection criteria.

• GCXX Blocks Ferroptosis in 5-FU Intestinal Mucositis

  2026-10-01

  A 2026 study reports that Gancao Xiexin decoction protects mice from 5-fluorouracil-induced intestinal mucositis by suppressing ACSL4- and MAPK-associated ferroptosis while activating Keap1-Nrf2 antioxidant signaling. Its combination of tissue phenotyping, pathway analysis, molecular docking, molecular dynamics, and DARTS identifies liquiritin as a candidate mediator, while also defining important limits for translation.

• PEG 400 and Quercetin: BCRP Efflux Mechanisms

  2026-10-01

  The reference study shows that PEG 400 can substantially increase quercetin exposure and anti-inflammatory activity through coordinated effects on solubility, UGT1A9-mediated metabolism, and BCRP/MRP2 efflux. Its integrated use of pharmacokinetics, spatial mass spectrometry imaging, transporter models, and an inflammation assay provides a stronger mechanistic framework than exposure measurements alone.

• NETs in CML: PAD4 and TKI Effects

  2026-09-30

  The reference study shows that neutrophil extracellular trap formation is elevated in chronic myeloid leukemia and is differentially altered by tyrosine kinase inhibitors. By combining patient-derived neutrophils with a BCR-ABL1 HoxB8 model and pathway inhibitors, it identifies PAD4-associated histone citrullination as a mechanistic component relevant to possible vascular toxicity.

• Hematoxylin and Eosin Staining Kit Guide

  2026-09-30

  The Hematoxylin and Eosin Staining Kit supports reproducible visualization of nuclei, cytoplasm, extracellular matrix, and overall tissue architecture in research specimens. It is intended for paraffin-embedded or frozen tissue sections and cytological preparations, not for clinical diagnosis or medical use.

• XPG Mutations and the Integrated Stress Response

  2026-09-29

  This study distinguishes a severe XP/CS phenotype from an XP-only phenotype caused by mutations in the same XPG gene. Its central finding is that the CS-associated cellular state includes impaired RNA polymerase I activity, defective rRNA maturation, eIF2α phosphorylation, and increased reliance on IRES-mediated translation, linking XPG pathology to ribosome homeostasis and the integrated stress response.

• Hoechst 33258 Workflows for KRas TNT Imaging

  2026-09-29

  Learn how to use Hoechst 33258 as a nuclear reference channel in live-cell, fixed-cell, confocal, and flow-cytometry workflows studying KRas transfer through tunneling nanotubes. Practical parameters, controls, and troubleshooting guidance help separate true biological changes from staining, efflux, and imaging artifacts.

• EZ Cap™ Cas9 mRNA (5-moUTP) Workflow

  2026-09-28

  Build transient CRISPR-Cas9 genome editing workflows for zebrafish and cell-based functional gene studies with a capped, modified Cas9 mRNA. This guide connects the Fyn–Stat3 neurodegeneration model to practical delivery, controls, optimization, and troubleshooting without overstating what the reference study demonstrated.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-09-28

  Masitinib (AB1010) is a DMSO-compatible kinase inhibitor for research requiring targeted study of KIT and PDGFRα/β, including KIT-mutant cell models and mast cell assays. It is not suited to aqueous or ethanol-based workflows, broad-spectrum kinase inhibition, or clinical treatment decisions; establish cellular working conditions in the specific assay rather than transferring biochemical values directly.

• Reversine and the Mitotic Checkpoint: A Research Guide

  2026-09-27

  Reversine is an Aurora kinase inhibitor for probing mitotic control and cancer cell responses. This guide connects Aurora kinase perturbation with mitotic checkpoint-complex research while clarifying what the evidence does—and does not—show.

8509 records 1/568 page Next 12345 下5页 Last page